Business
AMBU_B: Ambitious strategy aims for global endoscopy leadership, 11%-13% CAGR, and 20%+ EBIT margin
AMBU_B: Ambitious strategy aims for global endoscopy leadership, 11%-13% CAGR, and 20%+ EBIT margin
About this update from Ambu A/s Class B
A new growth strategy targets global endoscopy leadership through single-use innovation, digital solutions, and operational scale. Financial guidance is raised to 11%-13% organic CAGR and 20%+ EBIT margin by 2029/30, with disciplined M&A and a strong focus on people, sustainability, and customer-centricity.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.